There are 2185 resources available
LBA78 - Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
Presenter: Hans Gelderblom
Session: Proffered paper session: Sarcoma
Resources:
Abstract
1543MO - Analysis of concordance between trial and target populations for cancer drugs in the US, EU, and Switzerland (2014-2023)
Presenter: Kerstin Vokinger
Session: Mini oral session: Policy and preventive strategies
Resources:
Abstract
1172O - Akkermansia muciniphila-based multi-omic profiling in advanced non-small cell lung cancer
Presenter: Lorenzo Belluomini
Session: Proffered paper session 2: Basic science & Translational research
Resources:
Abstract
1242MO - The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: A randomized controlled, open-label phase II study
Presenter: JIE ZHANG
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
1144O - Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): Underlying molecular mechanisms
Presenter: Alberto Lens-Pardo
Session: Proffered paper session: NETs and endocrine tumours
Resources:
Abstract
LBA79 - LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib
Presenter: Jean-Yves Blay
Session: Proffered paper session: Sarcoma
Resources:
Abstract
1544MO - Clinical trial design and treatment effects: A meta-analysis of randomized-controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications
Presenter: Julia Caroline Michaeli
Session: Mini oral session: Policy and preventive strategies
Resources:
Abstract
1243MO - A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914
Presenter: Shota Omori
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
LBA64 - Outcomes of BRCA and in-house homologous recombination deficiency (HRD) testing in women with ovarian and breast cancer: A multicentre registry study
Presenter: Kyrillus Shohdy
Session: Mini oral session: Policy and preventive strategies
Resources:
Abstract
1545MO - Personalised cancer prevention programme (Interception): A cost analysis to inform public policy decision-making
Presenter: Farah Erdogan
Session: Mini oral session: Policy and preventive strategies
Resources:
Abstract